Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Mallinckrodt
Deloitte
US Department of Justice
Healthtrust
McKesson
Fuji
McKinsey

Generated: October 22, 2018

DrugPatentWatch Database Preview

TAMIFLU Drug Profile

« Back to Dashboard

When do Tamiflu patents expire, and when can generic versions of Tamiflu launch?

Tamiflu is a drug marketed by Roche and is included in two NDAs.

The generic ingredient in TAMIFLU is oseltamivir phosphate. There are seven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.

Drug patent expirations by year for TAMIFLU
Pharmacology for TAMIFLU
Medical Subject Heading (MeSH) Categories for TAMIFLU
Synonyms for TAMIFLU
(3R-(3alpha,4beta,5alpha)-Ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (1:1)
(3R-(3alpha,4beta,5alpha))-Ethyl 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (1:1)
(3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester phosphate
(3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid ethyl ester phosphoric acid salt
(3R,5S)-ethyl4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylate
1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3alpha,4beta,5alpha)-, phosphate (1:1)
1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-, phosphate
1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R,4R,5S)-, phosphate (1:1)
204255-11-8
255O118
4A3O49NGEZ
AB0011433
ABP000749
AC-25911
AC1L2U9Q
ACT03369
AK143302
AKOS015896056
BC216470
BCP9001033
BCPP000138
C08093
C16H28N2O4.H3O4P
C16H28N2O4.H3PO4
CCG-230250
CHEBI:7799
CHEMBL1200340
CS-0871
D00900
DTXSID0044230
Ebilfumin (TN)
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (1:1)
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate, phosphate (1:1)
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate phosphate
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate phosphate
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate; phosphoric acid
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate;phosphoric acid
ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate; phosphoric acid
GS-4104/002
GS4104
HY-17016
I06-1861
J-013302
J-523838
J10429
KS-1184
LS-173828
MCULE-3939535663
MFCD08059548
MLS006011559
MolPort-005-938-626
OR240134
Oseltamir Phosphate
Oseltamivir (phosphate)
Oseltamivir phosphate
Oseltamivir phosphate (impurity B free), European Pharmacopoeia (EP) Reference Standard
Oseltamivir phosphate (JAN/USAN)
Oseltamivir phosphate [USAN:USP]
Oseltamivir Phosphate [USAN]
Oseltamivir phosphate, >=98% (HPLC)
Oseltamivir Phosphate, pharmaceutical secondary standard; traceable to USP, PhEur
Oseltamivir phosphate, United States Pharmacopeia (USP) Reference Standard
Oseltamivirphosphate
Osteltamivir phosphate
PGZUMBJQJWIWGJ-ONAKXNSWSA-N
phosphoric acid ethyl (3R,4R,5S)-5-amino-4-acetamido-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
RL02533
Ro 64-0796
Ro 64-0796/002
Ro-64-0796-002
Ro-64-0796/002
Ro-640796002
s2597
SCHEMBL8730
SMR004703323
SR-05000001499
SR-05000001499-2
ST24048849
Tamiflu (TN)
UNII-4A3O49NGEZ
W-5362
Z1550675456

US Patents and Regulatory Information for TAMIFLU

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-003 Jul 2, 2007 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate FOR SUSPENSION;ORAL 021246-002 Mar 21, 2011 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-002 Jul 2, 2007 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for TAMIFLU

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-003 Jul 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate FOR SUSPENSION;ORAL 021246-002 Mar 21, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate FOR SUSPENSION;ORAL 021246-001 Dec 14, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TAMIFLU
Drugname Dosage Strength RLD Date
➤ Subscribe Oral Suspension 6 mg/mL ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Capsules 30 mg and 45 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Capsule 75 mg ➤ Subscribe ➤ Try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Mallinckrodt
Deloitte
US Department of Justice
Healthtrust
McKesson
Fuji
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.